• Tue, April 4, 2023
Robert Burns Maintained (YMAB) at Strong Buy with Decreased Target to $11 on, Apr 4th, 2023
Robert Burns of HC Wainwright & Co., Maintained "Y-mAbs Therapeutics, Inc." (YMAB) at Strong Buy with Decreased Target from $19 to $11 on, Apr 4th, 2023.
Robert has made no other calls on YMAB in the last 4 months.
There are 5 other peers that have a rating on YMAB. Out of the 5 peers that are also analyzing YMAB, 3 agree with Robert's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Etzer Darout of "Guggenheim" Downgraded from Strong Buy to Hold on, Monday, April 3rd, 2023
- Alec Stranahan of "B of A Securities" Maintained at Hold and Held Target at $6 on, Saturday, April 1st, 2023
- Joseph Thome of "Cowen & Co." Downgraded from Buy to Hold on, Thursday, January 5th, 2023
These are the ratings of the 2 analyists that currently disagree with Robert
- William Maughan of "Canaccord Genuity" Maintained at Strong Buy with Decreased Target to $18 on, Friday, March 31st, 2023
- Michael Ulz of "Morgan Stanley" Downgraded from Hold to Sell on, Friday, January 27th, 2023
